Abstract
Background and purpose: Anticoagulant and antiplatelets for prevention of ischaemic stroke and cardiovascular diseases may increase the risk of intracerebral hemorrhage (ICH). This study aimed to investigate the influence of pre-ICH use of anticoagulant and antiplatelets on ICH patients. Methods: Consecutive patients with acute spontaneous ICH registered in a single-center stroke registry during 2001 to 2010 were analyzed and categorized according to their pre-ICH use of warfarin (Group I), antiplatelets (Group II), or neither (Group III). Survival analysis and the Cox proportional hazard model were used to compare between the three groups and the predictors. Results: Of 2021 ICH patients (male, 63.3%; mean age, 62.6 ± 14.4 years) included, there were 94 (4.7%) in Group I, 232 (11.4%) in Group II, and 1695 (83.9%) in Group III. Warfarin users had larger hematoma volume, more intraventricular extension, higher frequencies of lobar ICH, and higher case fatality than non-warfarin users (Groups II and III). The Cox proportional hazard model showed increased 6-month case fatality in pre-ICH warfarin users (adjusted hazard ratio 2.75, 95% confidence interval 2.04-3.72, P
| Original language | English |
|---|---|
| Pages (from-to) | 1128-1134 |
| Number of pages | 7 |
| Journal | European Journal of Neurology |
| Volume | 20 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Aug 2013 |
Fingerprint
Keywords
- Anticoagulants
- Antiplatelet
- Cerebral hemorrhage
- Warfarin
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Cite this
Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients. / Chen, Y. W.; Tang, S. C.; Tsai, L. K.; Yeh, S. J.; Chiou, H. Y.; Yip, P. K.; Jeng, J. S.
In: European Journal of Neurology, Vol. 20, No. 8, 08.2013, p. 1128-1134.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pre-ICH warfarin use, not antiplatelets, increased case fatality in spontaneous ICH patients
AU - Chen, Y. W.
AU - Tang, S. C.
AU - Tsai, L. K.
AU - Yeh, S. J.
AU - Chiou, H. Y.
AU - Yip, P. K.
AU - Jeng, J. S.
PY - 2013/8
Y1 - 2013/8
N2 - Background and purpose: Anticoagulant and antiplatelets for prevention of ischaemic stroke and cardiovascular diseases may increase the risk of intracerebral hemorrhage (ICH). This study aimed to investigate the influence of pre-ICH use of anticoagulant and antiplatelets on ICH patients. Methods: Consecutive patients with acute spontaneous ICH registered in a single-center stroke registry during 2001 to 2010 were analyzed and categorized according to their pre-ICH use of warfarin (Group I), antiplatelets (Group II), or neither (Group III). Survival analysis and the Cox proportional hazard model were used to compare between the three groups and the predictors. Results: Of 2021 ICH patients (male, 63.3%; mean age, 62.6 ± 14.4 years) included, there were 94 (4.7%) in Group I, 232 (11.4%) in Group II, and 1695 (83.9%) in Group III. Warfarin users had larger hematoma volume, more intraventricular extension, higher frequencies of lobar ICH, and higher case fatality than non-warfarin users (Groups II and III). The Cox proportional hazard model showed increased 6-month case fatality in pre-ICH warfarin users (adjusted hazard ratio 2.75, 95% confidence interval 2.04-3.72, P
AB - Background and purpose: Anticoagulant and antiplatelets for prevention of ischaemic stroke and cardiovascular diseases may increase the risk of intracerebral hemorrhage (ICH). This study aimed to investigate the influence of pre-ICH use of anticoagulant and antiplatelets on ICH patients. Methods: Consecutive patients with acute spontaneous ICH registered in a single-center stroke registry during 2001 to 2010 were analyzed and categorized according to their pre-ICH use of warfarin (Group I), antiplatelets (Group II), or neither (Group III). Survival analysis and the Cox proportional hazard model were used to compare between the three groups and the predictors. Results: Of 2021 ICH patients (male, 63.3%; mean age, 62.6 ± 14.4 years) included, there were 94 (4.7%) in Group I, 232 (11.4%) in Group II, and 1695 (83.9%) in Group III. Warfarin users had larger hematoma volume, more intraventricular extension, higher frequencies of lobar ICH, and higher case fatality than non-warfarin users (Groups II and III). The Cox proportional hazard model showed increased 6-month case fatality in pre-ICH warfarin users (adjusted hazard ratio 2.75, 95% confidence interval 2.04-3.72, P
KW - Anticoagulants
KW - Antiplatelet
KW - Cerebral hemorrhage
KW - Warfarin
UR - http://www.scopus.com/inward/record.url?scp=84880109055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880109055&partnerID=8YFLogxK
U2 - 10.1111/j.1468-1331.2012.03847.x
DO - 10.1111/j.1468-1331.2012.03847.x
M3 - Article
C2 - 22897602
AN - SCOPUS:84880109055
VL - 20
SP - 1128
EP - 1134
JO - European Journal of Neurology
JF - European Journal of Neurology
SN - 1351-5101
IS - 8
ER -